- What we do
-
-
Routes of delivery
- Oral
- Nasal
- Nose to Brain
- Pulmonary
- Parenteral
-
Development stage
- Pre-clinical
- Phase I to Phase II
- Phase III - Commercial
Our Approach
- Selecting Your CDMO Partner
- Project Management
-
- About us
-
-
A CDMO like no other
- About Us
- Our Facilities
- Our History
- Awards and Achievements
-
Leadership Expertise
- Executive Leadership Team
- Board of Directors
- Careers
-
-
- Resources
- Events
- Contact
Home / Resources / Whitepapers
Soft Mist Inhalers: Lung deposition benefits for respiratory conditions

This whitepaper explores the growing role of Soft Mist Inhalers (SMIs) in respiratory drug delivery, highlighting their advantages in lung deposition, market growth, and formulation opportunities. It also examines device design, performance testing, and future directions for SMI development.
Whitepaper Contents
- An overview of the global inhalation market and SMI growth trends
- Insights into the design and function of Soft Mist Inhalers
- Discussion of how SMIs enhance lung deposition and patient outcomes
- Considerations for inhalation device selection in early development
- Use of the Next Generation Impactor (NGI) to assess lung deposition
- Opportunities for reformulating existing drugs for pulmonary delivery
- The Future outlook for SMIs